Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Clinical trial NCT06470971 · RECRUITING

Trial details

NCT number: NCT06470971
Sponsor: Yuanquan Yang
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Malignant Solid Neoplasm Hematopoietic and Lymphatic System Neoplasm

Start date: 2024-07-09
Primary completion: 2026-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.